{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:25Z","timestamp":1792800925466,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metaplastic breast carcinoma (MpBC) is a rare and highly heterogeneous breast malignancy. Although most cases exhibit a triple-negative phenotype, MpBC differs from conventional triple-negative breast cancer in its biological behavior, treatment response, and metastatic pattern. Neoadjuvant chemoimmunotherapy has become an important strategy for high-risk early-stage triple-negative breast cancer; however, the evidence supporting its use in MpBC remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 54-year-old woman was initially diagnosed with locally advanced triple-negative breast cancer of the left breast with ipsilateral axillary lymph node metastasis. A pembrolizumab-containing neoadjuvant regimen was initiated, with paclitaxel plus carboplatin as the initial chemotherapy backbone and planned sequential doxorubicin plus cyclophosphamide. After two cycles of initial neoadjuvant therapy, she developed recurrent high-grade fever, with extensive negative infectious workup and poor response to broad-spectrum antibiotics. Incision of the breast lesion revealed extensive gray-white necrotic tissue rather than typical purulent discharge. Multidisciplinary evaluation suggested tumor necrosis\u2013related fever, and a modified radical mastectomy was performed. Fever resolved rapidly after surgery, and inflammatory markers decreased. Postoperative pathology confirmed high-grade triple-negative metaplastic breast carcinoma with Miller-Payne grade 1 response, a Ki-67 index of approximately 75%, and no definite axillary lymph node metastasis. Despite postoperative systemic treatment adjustment, the patient developed lumbar and hip symptoms with suspicious bone and soft-tissue lesions and rapidly progressed to cachexia. She died of systemic failure 5 months after surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights that persistent fever during neoadjuvant chemoimmunotherapy in MpBC should prompt careful exclusion of infection, while tumor necrosis\u2013related fever and immune-inflammatory amplification should also be considered. In patients with suspected or confirmed MpBC who develop early tumor progression, necrosis, ulceration, fever, or deterioration in performance status, timely pathological review, reassessment of treatment response, and multidisciplinary decision-making are essential. Earlier surgery may be necessary to establish definitive pathology, control the local inflammatory source, and preserve subsequent treatment opportunities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1943838","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:48:00Z","timestamp":1789620480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Triple-negative metaplastic breast carcinoma with primary resistance to neoadjuvant chemoimmunotherapy, refractory tumor necrosis-related fever, and rapid postoperative disease progression"],"prefix":"10.3389","volume":"16","author":[{"given":"LinHong","family":"Hu","sequence":"first","affiliation":[{"name":"School of Medicine, Southwest Medical University of China, Department of Breast Surgery The Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiFan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Affiliated Hospital of Panzhihua University","place":["Panzhihua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Medicine, Southwest Medical University of China, Department of Breast Surgery The Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]},{"name":"Department of Breast Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16208","article-title":"A comprehensive overview of metaplastic breast cancer: Features and treatments","volume":"115","author":"Yan","year":"2024","journal-title":"Cancer Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635237","article-title":"A case series of metastatic metaplastic breast carcinoma treated with anti-Pd-1 therapy","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41523-021-00302-z","article-title":"Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma","volume":"7","author":"Wong","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2022.01.006","article-title":"Neoadjuvant chemotherapy for metaplastic breast cancer: Response rates, management, and outcomes","volume":"22","author":"Haque","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001760","article-title":"Pd-L1 expression in metaplastic breast carcinoma using the Pd-L1 Sp142 assay and concordance among Pd-L1 immunohistochemical assays","volume":"45","author":"Grabenstetter","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41523-025-00816-w","article-title":"Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer","volume":"11","author":"Abuhadra","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000015840","article-title":"Naproxen for the treatment of neoplastic fever: A Prisma-compliant systematic review and meta-analysis","volume":"98","author":"Zhang","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.15-3-292","article-title":"Malignant causes of fever of unknown origin","volume":"15","author":"Foggo","year":"2015","journal-title":"Clin Med (Lond)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01065-3","article-title":"Metaplastic breast cancers frequently express immune checkpoint markers Foxp3 and Pd-L1","volume":"123","author":"Kalaw","year":"2020","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18085-z","article-title":"Neoadjuvant chemotherapy is associated with worse 5-year overall survival in patients with metaplastic breast cancer compared with primary surgery: A national cancer database analysis","volume":"32","author":"Chichura","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-2182","article-title":"A multicenter phase Ii trial of Ipilimumab and Nivolumab in unresectable or metastatic metaplastic breast cancer: Cohort 36 of dual Anti-Ctla-4 and Anti-Pd-1 blockade in rare tumors (Dart, Swog S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-2857","article-title":"The landscape of somatic genetic alterations in metaplastic breast carcinomas","volume":"23","author":"Ng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679177","article-title":"Case report: Immune checkpoint inhibitor-induced exuberant tumor inflammation with accelerated clinical deterioration in metastatic renal cell carcinoma","volume":"11","author":"Gopalakrishnan","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005841","article-title":"Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Case report and systematic review of the literature","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2221-4","article-title":"Diagnosis of bone metastases: A meta-analysis comparing 18Fdg Pet, Ct, Mri and bone scintigraphy","volume":"21","author":"Yang","year":"2011","journal-title":"Eur Radiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01454-0","article-title":"Cancer cachexia: Molecular mechanisms and treatment strategies","volume":"16","author":"Setiawan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207746","article-title":"The impact of inflammation and acute phase activation in cancer cachexia","volume":"14","author":"Robinson","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943838\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:48:25Z","timestamp":1789620505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1943838\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":18,"alternative-id":["10.3389\/fonc.2026.1943838"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1943838","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1943838"}}